NBIX Neurocrine Biosciences Forecast, Technical & Fundamental Analysis

NBIX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on July 31, 2025

NBIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 36 cases where NBIX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 14, 2025. You may want to consider a long position or call options on NBIX as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NBIX just turned positive on August 15, 2025. Looking at past instances where NBIX's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

NBIX moved above its 50-day moving average on August 12, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for NBIX crossed bullishly above the 50-day moving average on August 20, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 264 cases where NBIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.115) is normal, around the industry mean (17.318). P/E Ratio (41.107) is within average values for comparable stocks, (73.434). Projected Growth (PEG Ratio) (0.360) is also within normal values, averaging (4.903). NBIX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (5.685) is also within normal values, averaging (41.941).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.